Predicting the individual clinical course remains a major issue in biomarker research in Alzheimer’s disease to adapt the therapeutic care of patients. Imaging data may contain valuable early markers of the clinical evolution of AD. In this study, we investigated the prognostic value of some imaging markers for the prediction of the clinical evolution of mild cognitive impairment (MCI) and AD patients over 24 months through both the conversion and the cognitive decline problems. With a rigorous validation scheme, for each clinical outcome, we built competitive predictive models on the ADNI cohort which are highly generalizable to other independent cohorts (OASIS and AddNeuroMed).
This abstract and the presentation materials are available to members only; a login is required.